Opioid Use Disorder Market Size was valued at USD 3.1 Billion in 2022. The Opioid Use Disorder market industry is projected to grow from USD 3.44 Billion in 2023 to USD 8.05 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.20% during the forecast period (2023 - 2032). Increased consideration of buprenorphine patches as an effective treatment mode and the rising focus of government & non-government institutions on creating awareness are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
In the Opioid Use Disorder (OUD) market, a prominent trend involves the increasing integration of telehealth services to enhance accessibility to treatment. Telehealth solutions provide a convenient and confidential platform for individuals struggling with OUD to access counseling, therapy, and medication-assisted treatment remotely. This trend not only addresses barriers related to stigma and geographic constraints but also supports ongoing care, contributing to more comprehensive and patient-centric approaches to managing opioid dependence. This factor drives the Market CAGR.
Additionally, the OUD market is witnessing significant advancements in Medication-Assisted Treatment (MAT), with the development of new medications and improved formulations. MAT combines pharmaceutical interventions with counseling and behavioral therapies to address opioid addiction comprehensively. Emerging medications, such as extended-release formulations or novel combination therapies, aim to enhance treatment efficacy, reduce withdrawal symptoms, and improve patient adherence. These innovations signify a commitment to refining therapeutic options and aligning with the evolving needs of individuals seeking effective and evidence-based interventions for Opioid Use Disorder.
A crucial trend in the Opioid Use Disorder market involves a heightened emphasis on harm reduction strategies. Recognizing the complex nature of addiction, there is a growing shift towards harm reduction initiatives that prioritize minimizing the negative consequences of Opioid Use rather than solely focusing on abstinence. This trend encompasses the widespread distribution of naloxone, supervised consumption sites, and needle exchange programs, aiming to prevent opioid overdoses and reduce the associated health risks. The focus on harm reduction reflects a more compassionate and pragmatic approach to addressing the multifaceted challenges posed by Opioid Use Disorder. For instance, in June 2022, Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implants to opioid addiction patients. Thus, driving the Opioid Use Disorder market revenue.
The Opioid Use Disorder market segmentation, based on Drug Type, includes Buprenorphine, Naltrexone, and Methadone. The Methadone category stands as the dominant category due to its long-acting opioid agonist properties, helping to alleviate withdrawal symptoms and cravings effectively. Its extensive history of use and proven efficacy in managing OUD contribute to its dominance, particularly in highly regulated clinical settings. Meanwhile, the fastest-growing category is Buprenorphine, recognized for its partial agonist properties, reducing the risk of overdose and abuse potential.
Figure 1: Opioid Use Disorder Market, by Drug Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Opioid Use Disorder market segmentation, based on Age Group, includes 19 to 40, 41 to 60, 61 and over. The 41 to 60 category represented the dominant category. This demographic dominance can be attributed to factors such as a higher likelihood of chronic pain issues, increased exposure to prescription opioids for medical reasons, and a longer duration of potential opioid use. However, the fastest-growing category is the age group of 19 to 40, reflecting a concerning trend of rising opioid misuse among younger individuals.
The Opioid Use Disorder market segmentation, based on Route of Administration, includes Intravenous and Oral. The dominant category is oral, primarily due to its practicality, safety, and ease of patient compliance. Oral administration is widely preferred for OUD treatment as it eliminates the potential complications associated with intravenous methods, such as infection risks and the need for specialized medical supervision during administration. Conversely, the fastest-growing category is intravenous administration, driven by the urgency and immediacy often required in emergency situations or critical cases of opioid dependence. Conversely, the fastest-growing category is intravenous administration, driven by the urgency and immediacy often required in emergency situations or critical cases of opioid dependence.
The Opioid Use Disorder market segmentation, based on Distribution Channel, includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies category dominated due to the complex nature of OUD treatment, often requiring specialized medications and close monitoring. Hospital pharmacies, equipped with healthcare professionals, facilitate the administration and management of medications, contributing to their dominant position. On the other hand, the fastest-growing category is online pharmacies, as the healthcare landscape evolves towards increased telehealth services. Online pharmacies provide a convenient and accessible platform for individuals seeking OUD treatment.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Opioid Use Disorder market area will dominate this market, owing to increased attention and resources towards addressing opioid-related issues, including prevention, treatment, and recovery. In addition, the growing number of established health clubs and fitness facilities will boost market growth in this region.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Opioid Use Disorder Market Share By Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Opioid Use Disorder market accounts for the second-largest market share due to the robust healthcare infrastructure, enabling the implementation of effective treatment and prevention strategies. Further, the German Opioid Use Disorder market held the largest market share, and the UK Opioid Use Disorder market was the fastest growing market in the European region
The Asia-Pacific Opioid Use Disorder Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to emerging awareness of opioid-related challenges in the region, leading to increased efforts to address and manage OUD. Moreover, China’s Opioid Use Disorder market held the largest market share, and the Indian Opioid Use Disorder market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Opioid Use Disorder market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Opioid Use disorder industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Opioid Use Disorder industry to benefit clients and increase the market sector. In recent years, the Opioid Use disorder industry has offered some of the most significant advantages. Major players in the Opioid Use Disorder market, including Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, Viatris Inc. and others, are attempting to increase market demand by investing in research and development operations.
Indivior was spun off from Reckitt Benckiser Group in 2014 and is headquartered in Slough, United Kingdom. The company is known for its focus on addiction treatment, particularly opioid addiction. Their flagship product is Suboxone, a medication that combines buprenorphine and naloxone, used for medication-assisted treatment of opioid dependence. Indivior has been involved in research and development to create innovative treatment options for addiction disorders and mental health conditions. The company's commitment extends to addressing the opioid crisis through various initiatives and collaborations aimed at providing effective and accessible solutions for individuals struggling with addiction. March 2023, Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. Opiant has investigational opioid overdose treatment candidate OPNT003. The acquisition will strengthen Indivior's position in addiction treatment
Collegium is known for its abuse-deterrent technology, which is designed to provide tamper-resistant formulations of certain medications to help prevent misuse or abuse. The company's flagship product is Xtampza ER, an extended-release oxycodone product indicated for the management of pain. Collegium Pharmaceutical, headquartered in Stoughton, Massachusetts, emphasizes responsible pain management practices and strives to balance the need for effective pain relief with measures to minimize the potential for abuse. They have been active in research and development to expand their product portfolio and address various pain management needs. March 2022, Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International Inc
June 2020: Titan Pharmaceuticals, Inc. and Indegene announced the formation of a multichannel digital marketing program in the U.S. to bolster their capability in terms of the provision of Probuphine implant for opioid-addicted patients.
February 2021: Orexo AB collaborated with ApexB.io and Magellan Rx Management to research the use of Modia. Modia is a digital therapeutic developed for patients suffering from Opioid Use DisorderOpioid Use Disorder Market Segmentation:
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 3.1 Billion |
| Market Size 2023 | USD 3.44 Billion |
| Market Size 2032 | USD 8.05 Billion |
| Compound Annual Growth Rate (CAGR) | 11.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Type, Age Group, Route of Administration, Distribution Channel and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc. Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, Viatris Inc. |
| Key Market Opportunities | · consideration of buprenorphine Patches as an effective treatment Mode |
| Key Market Dynamics | · rising focus of government & non-government institutions on creating awareness |
Frequently Asked Questions (FAQ) :
The Opioid Use Disorder market size was valued at USD 3.1 Billion in 2022.
The global market is projected to grow at a CAGR of 11.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Alkermes, Inc., Indivior PLC, BioDelivery Sciences International, Inc., Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corporation, Camurus, Hikma Pharmaceuticals PLC, AstraZeneca plc, Viatris Inc.
The Methadone category dominated the market in 2022.
The 41 to 60 had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
